| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
BRCA1 is an important breast and ovarian cancer susceptibility gene. Hereditary cancers with BRCA1 mutations and sporadic c ancers with lower BRCA1 expression are sensitive to platinating agent and PARP inhibitor. We identified a novel BRCA1-interacting protein (BIP) and found that overexpression of BIP causes reduction of BRCA1 and BARD1, which is also BRCA1-interacting protein. Interestingly, the expression level of BRCA1 and BIP show a negative correlation in several cancer cell lines. These suggest that the expression level of BIP is a candidate of biomarkers or molecular targets of cancer chemotherapy.
|
